197 related articles for article (PubMed ID: 31093663)
1. Pichia pastoris-expressed Zika virus envelope domain III on a virus-like particle platform: design, production and immunological evaluation.
Shanmugam RK; Ramasamy V; Shukla R; Arora U; Swaminathan S; Khanna N
Pathog Dis; 2019 Apr; 77(3):. PubMed ID: 31093663
[TBL] [Abstract][Full Text] [Related]
2. A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice.
Ramasamy V; Arora U; Shukla R; Poddar A; Shanmugam RK; White LJ; Mattocks MM; Raut R; Perween A; Tyagi P; de Silva AM; Bhaumik SK; Kaja MK; Villinger F; Ahmed R; Johnston RE; Swaminathan S; Khanna N
PLoS Negl Trop Dis; 2018 Jan; 12(1):e0006191. PubMed ID: 29309412
[TBL] [Abstract][Full Text] [Related]
3. Virus-like particles displaying envelope domain III of dengue virus type 2 induce virus-specific antibody response in mice.
Arora U; Tyagi P; Swaminathan S; Khanna N
Vaccine; 2013 Jan; 31(6):873-8. PubMed ID: 23261049
[TBL] [Abstract][Full Text] [Related]
4. Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies.
Poddar A; Ramasamy V; Shukla R; Rajpoot RK; Arora U; Jain SK; Swaminathan S; Khanna N
BMC Biotechnol; 2016 Jun; 16(1):50. PubMed ID: 27301568
[TBL] [Abstract][Full Text] [Related]
5. Dengue envelope-based 'four-in-one' virus-like particles produced using Pichia pastoris induce enhancement-lacking, domain III-directed tetravalent neutralising antibodies in mice.
Rajpoot RK; Shukla R; Arora U; Swaminathan S; Khanna N
Sci Rep; 2018 Jun; 8(1):8643. PubMed ID: 29872153
[TBL] [Abstract][Full Text] [Related]
6. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.
Liu Y; Zhou J; Yu Z; Fang D; Fu C; Zhu X; He Z; Yan H; Jiang L
BMC Microbiol; 2014 Dec; 14():233. PubMed ID: 25520151
[TBL] [Abstract][Full Text] [Related]
7. An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.
Urakami A; Ngwe Tun MM; Moi ML; Sakurai A; Ishikawa M; Kuno S; Ueno R; Morita K; Akahata W
J Virol; 2017 Dec; 91(23):. PubMed ID: 28956764
[TBL] [Abstract][Full Text] [Related]
8. Zika Virus-Like Particles Bearing a Covalent Dimer of Envelope Protein Protect Mice from Lethal Challenge.
De Lorenzo G; Tandavanitj R; Doig J; Setthapramote C; Poggianella M; Sanchez-Velazquez R; Scales HE; Edgar JM; Kohl A; Brewer J; Burrone OR; Patel AH
J Virol; 2020 Dec; 95(1):. PubMed ID: 33028720
[TBL] [Abstract][Full Text] [Related]
9. Zika virus envelope nanoparticle antibodies protect mice without risk of disease enhancement.
Shukla R; Shanmugam RK; Ramasamy V; Arora U; Batra G; Acklin JA; Krammer F; Lim JK; Swaminathan S; Khanna N
EBioMedicine; 2020 Apr; 54():102738. PubMed ID: 32305868
[TBL] [Abstract][Full Text] [Related]
10. Yeast-produced subunit protein vaccine elicits broadly neutralizing antibodies that protect mice against Zika virus lethal infection.
Zhang W; Qu P; Li D; Zhang C; Liu Q; Zou G; Dupont-Rouzeyrol M; Lavillette D; Jin X; Yin F; Huang Z
Antiviral Res; 2019 Oct; 170():104578. PubMed ID: 31394119
[TBL] [Abstract][Full Text] [Related]
11. Pichia pastoris-expressed dengue 2 envelope forms virus-like particles without pre-membrane protein and induces high titer neutralizing antibodies.
Mani S; Tripathi L; Raut R; Tyagi P; Arora U; Barman T; Sood R; Galav A; Wahala W; de Silva A; Swaminathan S; Khanna N
PLoS One; 2013; 8(5):e64595. PubMed ID: 23717637
[TBL] [Abstract][Full Text] [Related]
12. Development of Virus-Like-Particle Vaccine and Reporter Assay for Zika Virus.
Garg H; Sedano M; Plata G; Punke EB; Joshi A
J Virol; 2017 Oct; 91(20):. PubMed ID: 28794019
[TBL] [Abstract][Full Text] [Related]
13. Dengue and Zika Virus Domain III-Flagellin Fusion and Glycan-Masking E Antigen for Prime-Boost Immunization.
Lin HH; Yang SP; Tsai MJ; Lin GC; Wu HC; Wu SC
Theranostics; 2019; 9(16):4811-4826. PubMed ID: 31367259
[TBL] [Abstract][Full Text] [Related]
14. Pichia pastoris-expressed dengue virus type 2 envelope domain III elicits virus-neutralizing antibodies.
Batra G; Raut R; Dahiya S; Kamran N; Swaminathan S; Khanna N
J Virol Methods; 2010 Jul; 167(1):10-6. PubMed ID: 20211204
[TBL] [Abstract][Full Text] [Related]
15. Recombinant Dengue Virus 4 Envelope Glycoprotein Virus-Like Particles Derived from Pichia pastoris are Capable of Eliciting Homotypic Domain III-Directed Neutralizing Antibodies.
Khetarpal N; Shukla R; Rajpoot RK; Poddar A; Pal M; Swaminathan S; Arora U; Khanna N
Am J Trop Med Hyg; 2017 Jan; 96(1):126-134. PubMed ID: 27821688
[TBL] [Abstract][Full Text] [Related]
16. Tests in mice of a dengue vaccine candidate made of chimeric Junin virus-like particles and conserved dengue virus envelope sequences.
Mareze VA; Borio CS; Bilen MF; Fleith R; Mirazo S; Mansur DS; Arbiza J; Lozano ME; Bruña-Romero O
Appl Microbiol Biotechnol; 2016 Jan; 100(1):125-33. PubMed ID: 26386688
[TBL] [Abstract][Full Text] [Related]
17. Immunization with phage virus-like particles displaying Zika virus potential B-cell epitopes neutralizes Zika virus infection of monkey kidney cells.
Basu R; Zhai L; Contreras A; Tumban E
Vaccine; 2018 Feb; 36(10):1256-1264. PubMed ID: 29395533
[TBL] [Abstract][Full Text] [Related]
18. Zika Virus-Like Particle (VLP) vaccine displaying Envelope (E) protein CD loop antigen elicits protective and specific immune response in a murine model.
Cimica V; Williams S; Adams-Fish D; McMahon C; Narayanan A; Rashid S; Stedman TT
Biochem Biophys Res Commun; 2020 Aug; 529(3):805-811. PubMed ID: 32736711
[TBL] [Abstract][Full Text] [Related]
19. Zika virus-like particle (VLP) based vaccine.
Boigard H; Alimova A; Martin GR; Katz A; Gottlieb P; Galarza JM
PLoS Negl Trop Dis; 2017 May; 11(5):e0005608. PubMed ID: 28481898
[TBL] [Abstract][Full Text] [Related]
20. Zika virus-like particle vaccine protects AG129 mice and rhesus macaques against Zika virus.
Vang L; Morello CS; Mendy J; Thompson D; Manayani D; Guenther B; Julander J; Sanford D; Jain A; Patel A; Shabram P; Smith J; Alexander J
PLoS Negl Trop Dis; 2021 Mar; 15(3):e0009195. PubMed ID: 33711018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
